
Huy Q. Phan
Supervisory Patent Examiner (ID: 11630, Phone: (571)272-7924 , Office: P/2867 )
| Most Active Art Unit | 2617 |
| Art Unit(s) | 2858, 2685, 2687, 2617, 2867 |
| Total Applications | 523 |
| Issued Applications | 268 |
| Pending Applications | 57 |
| Abandoned Applications | 198 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16420425
[patent_doc_number] => 20200345623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => METHODS OF SCAR PREVENTION AND/OR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/865309
[patent_app_country] => US
[patent_app_date] => 2020-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865309
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/865309 | METHODS OF SCAR PREVENTION AND/OR TREATMENT | May 1, 2020 | Abandoned |
Array
(
[id] => 16328700
[patent_doc_number] => 20200299666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA
[patent_app_type] => utility
[patent_app_number] => 16/862706
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8910
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862706
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/862706 | MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA | Apr 29, 2020 | Abandoned |
Array
(
[id] => 17702893
[patent_doc_number] => 20220202899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => COMPOSITION FOR PREVENTION OR TREATMENT OF HAIR LOSS INCLUDING HAPLN1
[patent_app_type] => utility
[patent_app_number] => 17/607765
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6741
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607765
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607765 | COMPOSITION FOR PREVENTION OR TREATMENT OF HAIR LOSS INCLUDING HAPLN1 | Apr 28, 2020 | Abandoned |
Array
(
[id] => 17702889
[patent_doc_number] => 20220202895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => PULSATIVE GNRH ADMINISTRATION FOR TREATING COGNITIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/607676
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607676
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607676 | PULSATIVE GNRH ADMINISTRATION FOR TREATING COGNITIVE DISORDERS | Apr 28, 2020 | Pending |
Array
(
[id] => 17721618
[patent_doc_number] => 20220214340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => ZIPPER STRUCTURE THAT HELPS THE FORMATION OF PROTEIN DIMER AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/607007
[patent_app_country] => US
[patent_app_date] => 2020-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607007
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607007 | ZIPPER STRUCTURE THAT HELPS THE FORMATION OF PROTEIN DIMER AND APPLICATION THEREOF | Apr 25, 2020 | Pending |
Array
(
[id] => 17640658
[patent_doc_number] => 20220168396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/594259
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11775
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594259
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594259 | MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | Apr 9, 2020 | Pending |
Array
(
[id] => 16375112
[patent_doc_number] => 20200323954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => METHODS AND COMPOSITIONS FOR REDUCING GUT ISCHEMIA/REPERFUSION-INDUCED INJURY
[patent_app_type] => utility
[patent_app_number] => 16/844611
[patent_app_country] => US
[patent_app_date] => 2020-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23017
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844611
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/844611 | METHODS AND COMPOSITIONS FOR REDUCING GUT ISCHEMIA/REPERFUSION-INDUCED INJURY | Apr 8, 2020 | Abandoned |
Array
(
[id] => 16612181
[patent_doc_number] => 20210030834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => METHODS FOR ADMINISTERING ANGIOTENSIN II
[patent_app_type] => utility
[patent_app_number] => 16/831182
[patent_app_country] => US
[patent_app_date] => 2020-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15112
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831182
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/831182 | METHODS FOR ADMINISTERING ANGIOTENSIN II | Mar 25, 2020 | Abandoned |
Array
(
[id] => 17609925
[patent_doc_number] => 20220152204
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/440461
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440461
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/440461 | PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFOR | Mar 18, 2020 | Abandoned |
Array
(
[id] => 16341692
[patent_doc_number] => 20200306342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 16/819817
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 136252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819817
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/819817 | Nutritive polypeptides and formulations thereof, and methods of production and use thereof | Mar 15, 2020 | Issued |
Array
(
[id] => 16375040
[patent_doc_number] => 20200323882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => PHLIP(r)-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE
[patent_app_type] => utility
[patent_app_number] => 16/818527
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818527
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818527 | PHLIP(r)-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE | Mar 12, 2020 | Abandoned |
Array
(
[id] => 17342229
[patent_doc_number] => 20220008560
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2022-01-13
[patent_title] => TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A
[patent_app_type] => utility
[patent_app_number] => 16/818771
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818771 | Treatment of heart disease by disruption of the anchoring of PP2A | Mar 12, 2020 | Issued |
Array
(
[id] => 17342229
[patent_doc_number] => 20220008560
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2022-01-13
[patent_title] => TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A
[patent_app_type] => utility
[patent_app_number] => 16/818771
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818771 | Treatment of heart disease by disruption of the anchoring of PP2A | Mar 12, 2020 | Issued |
Array
(
[id] => 17577002
[patent_doc_number] => 20220133857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => ORAL FORMULATION AND TREATMENT OF PTH ANALOG
[patent_app_type] => utility
[patent_app_number] => 17/436416
[patent_app_country] => US
[patent_app_date] => 2020-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11876
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436416
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/436416 | ORAL FORMULATION AND TREATMENT OF PTH ANALOG | Mar 5, 2020 | Pending |
Array
(
[id] => 16108559
[patent_doc_number] => 20200206302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING INFLAMMATORY DISEASES AND THEIR SYMPTOMS
[patent_app_type] => utility
[patent_app_number] => 16/799609
[patent_app_country] => US
[patent_app_date] => 2020-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799609
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/799609 | USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING INFLAMMATORY DISEASES AND THEIR SYMPTOMS | Feb 23, 2020 | Abandoned |
Array
(
[id] => 20466602
[patent_doc_number] => 12522635
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-13
[patent_title] => Amyloid peptide variants
[patent_app_type] => utility
[patent_app_number] => 17/428615
[patent_app_country] => US
[patent_app_date] => 2020-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 2328
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/428615 | Amyloid peptide variants | Feb 23, 2020 | Issued |
Array
(
[id] => 16328449
[patent_doc_number] => 20200299415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS
[patent_app_type] => utility
[patent_app_number] => 16/796063
[patent_app_country] => US
[patent_app_date] => 2020-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796063
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/796063 | Method and carrier complexes for delivering molecules to cells | Feb 19, 2020 | Issued |
Array
(
[id] => 18084369
[patent_doc_number] => 11534476
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-27
[patent_title] => Methods for the prevention or treatment of heart failure
[patent_app_type] => utility
[patent_app_number] => 16/796940
[patent_app_country] => US
[patent_app_date] => 2020-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15240
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796940
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/796940 | Methods for the prevention or treatment of heart failure | Feb 19, 2020 | Issued |
Array
(
[id] => 16310678
[patent_doc_number] => 20200289416
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => DRUG DELIVERY VEHICLES FOR ATHEROSCLEROSIS NANOMEDICINE
[patent_app_type] => utility
[patent_app_number] => 16/792474
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792474
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/792474 | Drug delivery vehicles for atherosclerosis nanomedicine | Feb 16, 2020 | Issued |
Array
(
[id] => 16267366
[patent_doc_number] => 20200268853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/782773
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8229
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782773
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782773 | USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT | Feb 4, 2020 | Abandoned |